Crinetics PharmaceuticalsCRNX
Market Cap: $4.03B
About: Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Employees: 210
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 16
74% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 58
53% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $8.82M
16% more funds holding
Funds holding: 201 [Q1] → 233 (+32) [Q2]
0.61% more ownership
Funds ownership: 103.97% [Q1] → 104.57% (+0.61%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 13 [Q1] → 13 (+0) [Q2]
3% less capital invested
Capital invested by funds: $3.79B [Q1] → $3.69B (-$97.5M) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
HC Wainwright & Co. Douglas Tsao 50% 1-year accuracy 70 / 139 met price target | 37%upside $69 | Buy Maintained | 9 Aug 2024 |
Oppenheimer Leland Gershell 55% 1-year accuracy 27 / 49 met price target | 45%upside $73 | Outperform Reiterated | 9 Aug 2024 |
JP Morgan Jessica Fye 62% 1-year accuracy 23 / 37 met price target | 7%upside $54 | Overweight Maintained | 9 Jul 2024 |
Piper Sandler Yasmeen Rahimi 54% 1-year accuracy 15 / 28 met price target | 93%upside $97 | Overweight Maintained | 2 Jul 2024 |
HC Wainwright & Co. Douglas Tsao 50% 1-year accuracy 70 / 139 met price target | 19%upside $60 | Buy Reiterated | 28 Jun 2024 |
Financial journalist opinion
Based on 3 articles about CRNX published over the past 30 days